Quest Partners LLC Raises Stake in Zoetis Inc. (NYSE:ZTS)

Quest Partners LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 328.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,407 shares of the company’s stock after acquiring an additional 7,980 shares during the quarter. Quest Partners LLC’s holdings in Zoetis were worth $2,033,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Alpha Family Trust bought a new stake in Zoetis in the third quarter worth $213,000. Turtle Creek Wealth Advisors LLC increased its stake in Zoetis by 2.2% in the 3rd quarter. Turtle Creek Wealth Advisors LLC now owns 30,521 shares of the company’s stock worth $5,963,000 after purchasing an additional 664 shares during the period. Comgest Global Investors S.A.S. increased its stake in Zoetis by 21.6% in the 3rd quarter. Comgest Global Investors S.A.S. now owns 1,110,104 shares of the company’s stock worth $216,892,000 after purchasing an additional 197,240 shares during the period. KPP Advisory Services LLC lifted its position in Zoetis by 6.9% in the third quarter. KPP Advisory Services LLC now owns 5,344 shares of the company’s stock valued at $1,044,000 after purchasing an additional 344 shares during the last quarter. Finally, Natixis Advisors LLC boosted its stake in shares of Zoetis by 3.0% during the third quarter. Natixis Advisors LLC now owns 1,121,306 shares of the company’s stock valued at $219,081,000 after purchasing an additional 32,407 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Trading Up 0.7 %

NYSE ZTS opened at $176.42 on Tuesday. The firm has a market capitalization of $79.60 billion, a PE ratio of 33.16, a P/E/G ratio of 2.69 and a beta of 0.90. The stock’s 50 day moving average is $186.78 and its 200 day moving average is $180.45. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.36 EPS. Research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis’s payout ratio is presently 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.